Vir surges on up to $1.7B deal with Astellas to advance prostate cancer asset [Seeking Alpha]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Seeking Alpha
development and commercialization deal with Astellas Pharma ( ALPMF ) for the CD3 T-cell engager VIR-5500 for metastatic castration-resistant prostate cancer. Terms call for Astellas (
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US [Yahoo! Finance]Yahoo! Finance
- Astellas Pharma (OTCMKTS:ALPMY) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.MarketBeat
- Has Astellas Pharma (TSE:4503) Run Too Far After Its 61% One Year Share Price Jump? [Yahoo! Finance]Yahoo! Finance
- VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses [Yahoo! Finance]Yahoo! Finance
- VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc AnalysesPR Newswire